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Abstract
Purpose Since the adenosine A3 receptor (A3R) is considered
to be of high clinical importance in the diagnosis and treat-
ment of ischaemic conditions (heart and brain), glaucoma,
asthma, arthritis, cancer and inflammation, a suitable and se-
lective A3R PET tracer such as [18F]FE@SUPPYwould be of
high clinical value for clinicians as well as patients. A3R was
discovered in the late 1990s, but there is still little known
regarding its distribution in the CNS and periphery. Hence,
in autoradiographic experiments the distribution of A3R in
human brain and rat tissues was investigated and the specific
binding of the A3R antagonist FE@SUPPY and MRS1523
compared. Immunohistochemical staining (IHC) experiments
were also performed to validate the autoradiographic findings.
Methods For autoradiographic competition experiments hu-
man post-mortem brain and rat tissues were incubated with
[125I]AB-MECA and highly selective compounds to block the
other adenosine receptor subtypes. Additionally, IHCwas per-
formed with an A3 antibody.
Results Specific A3R binding of MRS1523 and FE@SUPPY
was found in all rat peripheral tissues examined with the
highest amounts in the spleen (44.0 % and 46.4 %), lung
(44.5 % and 45.0 %), heart (39.9 % and 42.9 %) and testes
(27.4 % and 29.5%, respectively). Low amounts of A3Rwere
found in rat brain tissues (5.9 % and 5.6 %, respectively) and
human brain tissues (thalamus 8.0 % and 9.1 %, putamen
7.8 % and 8.2 %, cerebellum 6.0 % and 7.8 %, hippocampus
5.7 % and 5.6 %, caudate nucleus 4.9 % and 6.4 %, cortex
4.9 % and 6.3 %, respectively). The outcome of the A3 anti-
body staining experiments complemented the results of the
autoradiographic experiments.
Conclusion The presence of A3R protein was verified in cen-
tral and peripheral tissues by autoradiography and IHC. The
specificity and selectivity of FE@SUPPY was confirmed by
direct comparison with MRS1523, providing further evidence
that [18F]FE@SUPPY may be a suitable A3 PET tracer for
use in humans.
Keywords Adenosine A3 receptor . CNS . Periphery .
Autoradiography .MRS1523 . FE@SUPPY
Introduction
Adenosine exerts its various effects via four different G-
protein-coupled receptors: adenosine A1, adenosine A2A,
adenosine A2B and adenosine A3 receptor (A1R, A2AR,
A2BR and A3R, respectively). The most recently discovered
receptor in the adenosine receptor family is the A3 subtype.
Since its discovery in the late 1990s, few data regarding the
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distribution and density of A3R in vivo have been reported
and are a matter of controversy [1]. Benarroch has stated that
the A3R is present in the hippocampus and cerebellum in
medium or low abundance [2]. Others have found A3R in
the thalamus and hypothalamus [3], an in the rat in the hippo-
campus [4, 5] and cortex [6]. In the periphery, high densities of
A3 mRNA have bee found in the spleen, lung, uterus and
testes. Medium density has been reported in the liver and
bladder, and low densities have been found in the heart, aorta,
stomach, jejunum, proximal colon, kidney and eyes [7]. Fur-
thermore, the presence of A3R has been confirmed in smooth
muscle tissue of blood vessels and the aorta of rats [8].
Since, A3R is considered to be of high clinical importance
in the diagnosis and treatment of ischaemic conditions (heart
and brain), glaucoma, asthma, arthritis, cancer and inflamma-
tion [9], all authors agree that there is an urgent need for a
ligand with high affinity and selectivity for the visualization of
A3R in vivo. Since PET allows noninvasive visualization and
quantification of receptor systems in vivo, a suitable A3R PET
tracer would be of high value for the evaluation of the pres-
ence of A3R, both in vitro and in vivo. Hence, we developed
and introduced [18F]FE@SUPPY as the first PET tracer
targeting A3R [10, 11]. In the meantime, other potential PET
tracers including a 76Br-labelled compound [12],
[18F]FE@SUPPY:2 [13, 14] and recently, 11C-labelled 1,2,4-
triazolo[4,3-α]quinoxalin-1-one derivatives [15] have been
synthesized and their affinity for A3R evaluated. So far, in
successful preclinical evaluations, [18F]FE@SUPPY [14, 16,
17] has shown an elevated brain to blood ratio in rats [11], and
metabolic stability in vitro and ex vivo in the brain for 30 min
[16], indicating that [18F]FE@SUPPY could potentially be
useful for PET imaging studies in humans.
Hence, as next steps in the preclinical evaluation process,
in this study autoradiographic experiments were performed to
determine the distribution of A3R in human brain regions
(hippocampus, thalamus, cortex, caudate nucleus, putamen
and cerebellum), in coronal rat brain tissues and in rat periph-
eral tissues (testes, heart, lung and spleen), and to compare the
specific binding (SB) of the A3R antagonist FE@SUPPY
(that is, the unlabelled standard compound of the A3R PET
tracer [18F]FE@SUPPY) and the structurally related A3R an-
tagonist MRS1523 (Fig. 1). Immunohistochemical staining




Human post-mortem brain tissues were collected following
local regulations for diagnostic purposes. Anonymized tissue
samples remaining after the diagnostic evaluation were used
in this project in the context of a study (BMolecular neuropath-
ologic investigation of neurodegenerative diseases^; collec-
tion of biological samples named BCJD KIN-Biobank^) ap-
proved by the Ethics Committee of the Medical University of
Vienna (No. 396/2011) and followed the principles of the
Declaration of Helsinki.
Autoradiographic experiments
Tissue from six different anatomical human brain regions
(hippocampus, thalamus, cortex, caudate nucleus, putamen
and cerebellum, n=2) was quick-frozen in isopentane (2-
methylbutane, CAS 78-78-4; Sigma Aldrich, Austria) at
−45 °C. Four male wild-type rats (200–300 g) were deeply
anaesthetized with diethylether and rapidly decapitated. Rat
organs (brain, testes, heart, lung and spleen) were removed
and subsequently quick-frozen as described for human tissues.
Frozen tissues were cut in a microcryotome (Thermo Scien-
tific Microm HM 560; HistoCom, Austria) into 10-μm thick
tissue slices, thaw-mounted on microscope slides (Thermo
Scientific, Menzel-Gläser SuperFrost® Plus; Braunschweig,
Germany), dried and stored at −40 °C until processing. A
barrier pen was purchased from Invitrogen (Mini PAP PEN;
Zymed Laboratories, Carlsbad, CA).
The standard compound FE@SUPPY (5-ethyl 2,4-
d ie thy l -3- ( (2- f luoroe thyl )su lphanylcarbonyl ) -6-
phenylpyridine-5-carboxylate) was synthesized at the
Department of Drug and Natural Product Synthesis of
the University of Vienna, Austria [19]. The A3R
radioligand [125I]AB-MECA (NEX312; A3R agonist,
0.59 nM [20]) and the Cyclone phosphor imager (Cy-
clone Plus storage phosphor system) and phosphor im-
ager plates (MS multisensitive phosphor screens long
type) were purchased from Perkin Elmer (Waltham,
MA), and lead-shielded autoradiography cassettes from
Fisher Scientific (Pittsburgh, PA).
EDTA (ethylenediaminetetraacetic acid), NaCl, adenosine
deaminase (ADA) and instant thin layer chromatography
(ITLC) paper (TLC silica gel 60 RP-18) were purchased from
Merck, Austria. DPCPX (CAS 102146-07-6), SCH442416
(CAS 316173 -57 -6 ) , MRS1754 (MDL numbe r
MFCD11046004) and MRS1523 (MDL number
Fig. 1 A3R antagonists FE@SUPPY and MRS1523. Chemical
structures of the 1,4-dihydropyridines
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MFCD03787977) and all other chemicals were purchased
from Sigma Aldrich, Austria.
Immunohistochemical staining
Primary antibody (sc-13938, anti-adenosine A3-R) was pur-
chased from Santa Cruz Biotechnology, CA. Secondary anti-
body (biotinylated anti-rabbit IgG), avidin-biotin complex
(Vectastain ABC kit, PK 4001) and aqueous mounting medi-
um (VectaMount) were obtained from Vector Laboratories,
CA. DAB substrate kit (ab 94665) was purchased from
Abcam (UK). Phosphate-buffered saline (PBS, pH 7.4, 10x
solution) was purchased fromMorphisto Evolutionsforschung
und Anwendung GmbH (Germany). Hydrogen peroxide
(H2O2), haemalum, ethanol and n-butyl acetate were pur-
chased fromMerck (Germany). Histofluid was obtained from
Paul Marienfeld GmbH & Co. KG (Germany), cover plates
(24 × 60 mm) were purchased fromMenzel-Gläser HistoCom
(Austria). All other chemicals were obtained from Sigma Al-
drich (Austria). Optical and metric analysis of the stained tis-




Tissues were surrounded with a hydrophobic barrier using a
barrier pen and were preincubated at room temperature for
30 min with a 50 mM Tris-HCl buffer solution (pH 7.4) con-
taining 1 mM EDTA, 100 mM NaCl and 2 U/ml ADA. After
preincubation, the tissue sections were washed in binding buffer
(50 mMTris-HCl buffer, pH 7.4) and air-dried. Slices were then
incubated directly with a solution containing the A3R
radioligand [125I]AB-MECA (0.7 nM) and the dedicated highly
selective adenosine receptor subtype blocking agents (Table 1).
It is noteworthy that the radioligand [125I]AB-MECA
shows affinity towards both adenosine receptors A1R and
the A3R [20, 24]. The explanation for this is a 49 % sequence
homology of the two proteins [25]. Therefore, to ensure com-
plete blocking of A1R, as well as of A2AR and A2BR, the
various competitors were used at concentrations 1,000-fold of
their inhibition constants (Ki) as listed in Table 1. Further-
more, the concentrations of the competitors used were also
adapted to varying Ki values according to the species differ-
ences of the A3R between rats and humans (Table 1).
In detail, the different incubation solutions for the human
tissues included the radioligand [125I]AB-MECA (0.7 nM),
DPCPX (A1R, 460 nM), SCH442416 (A2AR, 48 nM),
MRS1754 (A2BR, 1.97 μM), and MRS1523 (A3R, 19 μM)
or FE@SUPPY (A3R, 4.2 μM) in the binding buffer. For the
rat tissues, the incubation solutions included the radioligand
[125I]AB-MECA (0.7 nM), DPCPX (460 nM), SCH442416
(500 nM), MRS1754 (1.97 μM), and MRS1523 (113 μM) or
FE@SUPPY (600 μM) in the binding buffer. Target tissues
were incubated under optimum reaction conditions (60 min,
room temperature) in a lead-shielded cell. After incubation,
tissues were washed with buffer, rinsed with ice-cold water,
and dried. Samples were then placed on the phosphor imager
plates for exposure (9–14 days) in dedicated lead-shielded
cassettes. Autoradiographic images were analysed with a Cy-
clone phosphor imager and data were analysed with
OptiQuant data processing software version 5.0 andMicrosoft
Excel 2007.
Immunohistochemical staining
IHC experiments were performed according to a stan-
dard protocol [26] on vicinal tissue samples of the hu-
man and rat tissues used for autoradiography. First, the
tissues were fixed for 2 min in acetone/methanol (1:1).
The tissues were then incubated with 0.3 % hydrogen
Table 1 Selective compounds for the adenosine receptors (A1, A2A, A2B and A3)
Compound Receptor Ligand Species Affinity (nM) Reference Selectivity vs. other ARs
DPCPX A1 Antagonist Human nd nd
Rat Ki 0.46 [21] 740-fold vs. A2
SCH442416 A2A Antagonist Human Ki 0.48 [22] 23,000-fold vs. A1
Rat Ki 0.5 nd
MRS1754 A2B Antagonist Human Ki 1.97 [23] 200-fold vs. A1, 290-fold vs. A2A, 290-fold vs. A3
Rat nd nd
MRS1523 A3 Antagonist Human Ki 18.9 [18] 530-fold vs. A1, 190-fold vs. A2A
Rat Ki 113 140-fold vs. A1, 20-fold vs. A2A
FE@SUPPY A3 Antagonist Human Ki 4.2 [18] nd
Rat Ki 600 19-fold vs. A1, 12-fold vs. A2A
[125]AB-MECA A3, A1 Agonist Human Kd 0.59 [20, 24] nd
nd no data
930 Eur J Nucl Med Mol Imaging (2015) 42:928–939
peroxide for 30 min to block endogenous peroxidase
activity and incubated with an appropriate blocking se-
rum (goat) for 30 min to prevent nonspecific binding
(NB). The tissue slices were then incubated with the
primary antibody (rabbit) diluted 1:100 for 17 h at
4 °C. The tissue slices were incubated for 30 min with
biotinylated secondary antibody (anti-rabbit) and the av-
idin biotin complex prepared according to the manufac-
turer’s instructions. The slices were then incubated for
1–2 min with freshly prepared DAB solution. Tissues
were washed twice with PBS for 5 min between each
step, except after the incubation with the blocking se-
rum. As a reference in each tissue, the nuclei were
additionally stained with haemalum. To achieve perma-
nent staining, tissues were dehydrated with alcohol and
n-butyl acetate and covered with Histofluid. As a posi-
tive control, rat testicular tissue was stained in every
IHC experiment. As a negative control each tissue was
stained in parallel with and without antibody (with bind-
ing buffer to compensate for the amount of liquid). Fi-




All values are given as arithmetic means±standard deviation.
To determine the significance of differences, a two-tailed t test
with α=0.95 was performed using the statistics add-on in
Windows Excel 2010. Values of P≥0.05 were considered
not significant.
Analysis of the phosphor imager values
The phosphor imager software (OptiQuant) expresses the ra-
dioactive signal from the probes in digital light units per
square millimetre (DLU/mm2). The intensity of the light from
the stored energy is proportional to the amount of activity in
the sample. Therefore, aliquots of five concentrations of
radioligand stock solutions were spotted onto ITLC paper,
allowed to dry and placed on the phosphor film. After scan-
ning, a calibration curve based on the concentrations of the
aliquots was established. Then, the amount of standards
(kilobecquerels) and the phosphor imager signals (DLU/
mm2) derived from the probes were correlated. With the
known specific activity of the radioligand and the equation
from the linear regression curve (y = kx + d), the correspond-
ing relative concentration (femtomoles per square millimetre)
of receptor was calculated. To receive the DLU/mm2 values
from the probes, regions of interest (ROIs) were drawn for
each tissue of each experiment. DLU/mm2 values were nor-
malized to percentage values to enable comparison of the data
from the different experiments.
Consequently, autoradiographic experiments were
analysed in a “two-step” scheme as shown in Fig. 2. In detail,
in step 1 baseline values (reflecting the total binding of the
radioligand on the tissue) were set to 100 %, and competition
was expressed relative to this value. After blocking of the A1/
A2 receptors (A1R, A2AR, A2BR) the A3R binding and NB
was left. Therefore, in step 2, further blocking with the A3R-
selective antagonists MRS1523 or FE@SUPPY led to further
competition of the radioligand leaving NB remaining.
The following equations were used for analysis of the
data:
BL ¼ 100% ¼ total binding of the radioligand 125I AB‐MECA ¼ A1þ A2Aþ A2Bþ A3þ NB
BL− A1 þ A2A þ A2Bð Þ ¼ A3 þ NB ¼ BLA3 ¼ Baseline A3
BLA3− A3 ¼ NB
Fig. 2 BTwo-step^ analysis
scheme of the comparative
autoradiographic experiments
(BL baseline binding, NB
nonspecific binding, BLA3
remaining A3R and nonspecific
binding, called BBaseline A3^)
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Thus, SB of the two A3R antagonists was characterized
indirectly through competition, and was calculated as follows:
SB ¼ BL−NB
SB ¼ A1 þ A2A þ A2Bð Þ−NB
¼ specific A3 binding in relation to Baseline
Analysis of the IHC tissues
A3R antibody-stained tissues were analysed visually using a
Panoramic DESK scanner with a 40-fold magnification. Each
tissue was compared with a corresponding negative control
tissue without antibody. For differentiation of nuclei and other
cell compartments, additional haemalum staining was con-
ducted. Rat brain tissues were correlated with a rat brain atlas
(Paxinos) for determination of bregma and identification of
the different brain areas.
Results
Autoradiographic experiments
An general overview of the A3R (expressed as SB and relative
receptor density) obtained with the A3R antagonists
MRS1523 and FE@SUPPY in human brain, rat brain and
rat peripheral tissues is given in Table 2. Statistical analysis
(t tests) revealed no significant differences between the two
compounds.
Human brain regions
Autoradiographic images of [125I]AB-MECA competi-
tion under baseline and blocking conditions of six dif-
ferent human brain regions (hippocampus, thalamus,
cortex, caudate nucleus, putamen and cerebellum) are
shown in Fig. 3. High densities of A1R and A2Rs were
shown in all regions by drastic decreases in radioligand
binding after blocking with these receptors (Fig. 3b).
Further blocking of the A3R led to the SB values given
in Table 2.
Rat tissues
Autoradiographic images of [125I]AB-MECA competition un-
der baseline and blocking conditions on rat brain tissues are
shown in Fig. 4.
Autoradiographic images of [125I]AB-MECA competition
under baseline and blocking conditions on rat peripheral tis-
sues (testes) are shown in Fig. 5.
Immunohistochemical staining
A3R antibody staining (n=3–5) 3–5 different staining experi-
ments in human brain (Fig. 6), rat brain (Fig. 7) and rat peripheral
tissues (Fig. 8) showed staining in all tissues. As a reference




A3R is highly overexpressed in cancer cell lines and cancer
tissues [27–32] and in human enteric neurons [33] but not in
the majority of normal tissues [34]. Hence, its role as a tumour
marker and a target for tumour intervention and imaging is
undisputed [34, 35]. Furthermore, A3 antagonists are current-
ly discussed as a potential new approach to the treatment of
cancer [9, 31, 32]. The A3Rs are also known to be involved in
Table 2 Overview of SB of the
A3R obtained with the
antagonists MRS1523 and
FE@SUPPYvs. [125I]AB-MECA
on rat and human tissue origin
Values are means±standard
deviations from quadruple
analyses from two to four
different experiments each
?(n≤16)
a From Ribeiro et al. [45]




Human Hippocampus 5.7±0.3 5.6±0.7 0.39 A1, A3
Thalamus 8.9±4 9.1±1 0.79 A1, A2A, A3
Cortex 4.9±1 6.3±4 0.40 A1, A2A
Caudate nucleus 4.9±2 6.4±3 0.43 A1, A2A
Putamen 7.8±0.3 8.2±1 0.84 A2A, A1
Cerebellum 6.0±2 7.8±1.2 0.50 A2A, A1
Rat Brain 5.9±1.5 5.6±1.2 0.39 A1–3
Testes 27.4±6 29.5±3 1.20 A3 medium to high
Heart 39.9±6 42.9±4 3.10 A3 medium to low
Spleen 44±10 46.4±11 6.00 A3 medium to high
Lung 42.5±4 45.0±5 2.60 A3 medium to high
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cardiac diseases [36], cerebral ischaemia [37], glaucoma [38],
stroke [39] and epilepsy [40]. Hence, the value of A3 antago-
nists as pharmaceutical tools is obvious and a dedicated PET
tracer for in vivo visualization A3Rs would be of high value
for clinicians as well as patients.
Generally, it is well known that A3R is expressed at low
levels in the whole organism [41], as well as in the brain [1–6],
especially compared to the high expression rates of the A1R
and A2AR in the CNS. According to the literature, A1R is
abundant in most regions of the brain, with high densities in
the hippocampal area, cerebellum and cortex, and A2AR has
high densities in the basal ganglia, nucleus accumbens and
olfactory tubercle [42]. Furthermore, A3R differs widely be-
tween humans and rats, with only 72 % homology of the two
proteins [43], in contrast to general rat/human protein homol-
ogies of about 90–98 %. It is well known that 1,4-
dihydropyridines (such as MRS1523 and FE@SUPPY) dis-
play rather low affinities towards the rat A3R in comparison to
the human A3R. However, according to Müller and Jacobson,
MRS1523 can be considered a Buseful tool^ amongst the A3R
antagonists [44]. FE@SUPPY is structurally closely related to
MRS1523 (Fig. 1) with a lower Ki towards the rat A3R and a
higher Ki for the human A3R (Table 3).
In summary, the low expression rate of A3R in vivo, the
differences in A3R protein between humans and rats, and its
reported Benigmatic^ behaviour, as well as the results of some
other studies and the conclusions drawn by their authors as to
the whereabouts of A3R, create the impression that A3R
seems to be playing hide and seek. Hence, in the present
autoradiographic study we investigated the distribution and
presence of the A3R protein in the CNS and periphery using
two A3R antagonists, MRS1523 and FE@SUPPY, and vali-
dated the findings by IHC with a dedicated A3 antibody as a
specific imaging method.
Fig. 3 Representative autoradiographic images of [125I]AB-MECA
(0.7 nM) binding under baseline and blocking conditions in six
different human brain regions (ed highest uptake, white/grey complete
blocking): a baseline; b baseline A3 (i.e. after blocking of A1, A2A,
A2B; see Fig. 2); c additional blocking of the A3R with 19 μM
MRS1523; d additional blocking of the A3R with 4.2 μM
FE@SUPPY. Note that the Bactivity circle^ surrounding the brain
tissues is caused by tracer uptake by the lipophilic barrier pen; therefore
the ROIs were drawn inside precisely around the tissues of interest
Fig. 4 Representative autoradiographic images of [125I]AB-MECA
(0.7 nM) binding in coronal rat brain (bregma −2,30) under baseline
and blocking conditions. High blockable uptake was found in the
hippocampus, striatum/caudate putamen, medial globus pallidus (red
highest uptake, white/grey full competition): a baseline; b baseline A3
(i.e. after blocking of A1, A2A, A2B; see Fig. 2); c additional blocking of
the A3R with 113 μMMRS1523; d additional blocking of the A3R with
600 μM FE@SUPPY. Note that the Bactivity circle^ surrounding the
brain tissues is caused by tracer uptake by the lipophilic barrier pen;
therefore ROIs were drawn inside precisely around the tissues of interest
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Autoradiographic experiments
The autoradiographic experiments showed the presence of
A3R in all tissues examined. Using the scheme shown in
Fig. 2, A3R SB values for MRS1523/FE@SUPPY in human
brain regions were calculated (Table 2). The P values for SB in
human brain ranged from 0.4 to 0.8, in rat brain the P value
was 0.9, and in rat peripheral tissues the P values ranged from
0.5 to 0.8. Since all the tissues showed significant differences
between MRS1523 and FE@SUPPY throughout the whole
autoradiographic set-up, we conclude that the two ligands
are comparable in regard to their binding and blocking
behaviour.
Human brain regions
In human post-mortem brain, blocking the A1, A2A and the
A2B receptors drastically reduced the binding of [125I]AB-
MECA to 13–27 %, respectively (Fig. 9). This decrease in
radioligand binding can be explained by the low A3R/A1R
selectivity of [125I]AB-MECA and the high abundance of the
A1R in most brain regions. Blocking A3R with the selective
Fig. 6 Immunohistochemical staining of A3R in human brain regions
(n=3–5): a hippocampus, b cortex, c caudate nucleus, d putamen, e
thalamus, f cerebellum, g intracerebral artery, thalamus. Left of each
image pair A3R antibody staining indicated by red arrows; right of
each image pair control without A3R antibody; blue nuclei resulting
from haemalum staining (×40, scale bars 50 μm)
Fig. 5 Representative autoradiographic images of [125I]AB-MECA
(0.7 nM) binding under baseline and blocking conditions in rat testes
(red highest uptake, white/grey full competition): a baseline; b baseline
A3 (i.e. after blocking of A1, A2A, A2B; see Fig. 2); c additional blocking
of the A3R with 113 μM MRS1523; d additional blocking of the A3R
with 600 μMFE@SUPPY. Note that the Bactivity circle^ surrounding the
brain tissues is caused by tracer uptake by lipophilic barrier pen; therefore
ROIs were drawn inside precisely around the tissues of interest
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Fig. 7 Immunohistochemical
staining of A3R in rat brain
regions (n=3–5): a bregma 2,70
(nucleus accumbens), b bregma
4,70 (lateral olfactory tract), c
bregma −6,30 (hippocampal
fissure), d bregma −10,04
(superior cerebellar peduncle), e
bregma −6,30 (artery from the
hilus of dentate gyrus). Left of
each image pair A3R antibody
staining indicated by red arrows;
right of each image pair control
without A3R antibody; blue
nuclei resulting from haemalum
staining (×40, scale bars 50 μm)
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A3R antagonist MRS1523 or with FE@SUPPY led to a fur-
ther specific competition of the radioligand in all human brain
regions examined. Since all other ARs which could have in-
terfered were already blocked, this further reduction of
radioligand binding reflects selective A3R competition of
the radioligand, and therefore the presence of the A3R protein
in the tissues of interest (Table 2).
In detail, the hippocampus, a region widely considered to
show moderate to low densities of A3R [2], showed a moder-
ate density of A3R in this study. The thalamus is considered
by some to show a high density of A3R [3], which is in
accordance with this study in which the thalamus showed
the highest density of A3R. The observed medium to low
density of A3R in the cortical tissues is partly in accordance
with the literature, where cortex is sometimes even considered
as a nontarget region for A3R. In contrast, we found A3R in
the basal ganglia (caudate nucleus and putamen). In
accordance with Ribeiro et al. [45], we found medium
amounts of A3R in the cerebellum (Table 2). As shown in
Fig. 3, white matter regions including the cortex and cere-
bellum seemed to accumulate slightly more radiotracer
(leading to more baseline and background activity in the
tissues). Both regions showed the highest amounts of
Baseline A3 (27 % and 24 %, respectively) as shown in
Fig. 8, indicating lower A1 densities than in the grey
matter brain regions. Nevertheless, since A3R (and
A1R) are present in both, conclusive delineation of the
abundance of A3R between white and grey matter is not
possible at this point. However, the A3R antagonists
revealed the presence of A3R in the white matter, and this
may indicate the potential for imaging neurological
diseases involving the white matter, as suggested by
González-Fernández et al. who found that activation of
A3Rs may induce white matter death [46].
Fig. 8 Immunohistochemical
staining of A3R in rat peripheral
tissues (n=3–5): a testes, b heart,
c spleen, d lung. Left of each
image pairA3R antibody staining
indicated by red arrows; right of
each image pair control without
A3R antibody; blue nuclei
resulting from haemalum staining
(×40, scale bars 50 μm)
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Rat tissues
In rat brain, blocking of A1, A2A and A2B receptors led to a
drastic reduction (as observed in human brain tissues) in the
total binding of [125I]AB-MECA to 21 % remaining activity
defined as BBaseline A3^ (Fig. 9). Interestingly, in the rat
peripheral organs the reduction in radioligand binding was
less pronounced, ranging from 25 % to 45 % (Fig. 9), the
reason for which is as explained in the previous section.
MRS1523 and FE@SUPPY led to an additional decrease in
binding from Baseline A3 leading to the SB values given in
Table 2. In the periphery, the highest presence of A3 was
found in the spleen, followed by the lung, heart and testes.
A3 was also found in all these tissues by Dixon et al. at the
mRNA level [7].
Immunohistochemical staining
Optical analysis of the A3 antibody-stained tissues revealed
A3 in all central and peripheral regions examined. These find-
ings are in accordance and direct correlation with the autora-
diographic experiments and with literature [7]. In detail, both
protein level imaging methods (IHC and autoradiography)
confirmed the presence of A3 in the following regions in both
humans and rats: hippocampal area, cerebellar region, and
basal ganglia including the caudate nucleus and putamen. In
rat brain, A3R antibody staining was found in the hippocam-
pus, cerebellum and cingulate cortex (Fig. 6), as well as stain-
ing of intracerebral arteries (Fig. 7), which is in accordance
with the findings of Di Tullio et al. who specifically identified
A3R in rat pial and intracerebral arteries [47]. Interestingly, in
human brain regions, intracerebral arteries also showed spe-
cific A3 staining, as seen for example in the thalamic region
(Fig. 6). These findings are in accordance with the well-
known fact that the A3R is involved in the central regulation
of arterial blood pressure [8, 48].
Conclusion
In summary, if one looks thoroughly into the literature, A3R
sometimes appears to play hide and seek. Different findings in
regard to the presence and density of the A3R have been
shown by – amongst others – various in vitro methods, where
different targets are measured (e.g. A3 mRNA vs. A3R pro-
tein). As is well known, data from mRNA do not necessarily
reflect the presence of expressed protein. In this study, using
in vitro autoradiography and IHC, the A3R protein itself was
visualized and quantified.
The comparative autoradiographic evaluation of the A3R
in human post-mortem tissues from six different brain regions,
and rat coronal brain and peripheral tissues revealed the reli-
ably measurable presence of A3R in all investigated tissues.
The specific A3R binding of the two A3R antagonists
MRS1523 and FE@SUPPY in CNS and peripheral tissues
showed high correlations in all regions (Table 2). Hence, we
conclude that the two ligands can be considered comparable in
regard to their selectivity and specificity for A3R binding.
Since A3R overexpression is associated with a variety of
diseases including cancer and neurological pathologies, there
Fig. 9 Reductions in binding of
[125I]AB-MECA from 100 %
(total binding) to BBaseline A3^.
The red parts of the bars indicate
the amounts of A1R and A2R; the
corresponding blue parts indicate
the remaining amounts of
radioligand (i.e. remaining A3R
and nonspecific binding, defined
as BBaseline A3^). The data
presented are the means of three
or four autoradiographic
experiments
Table 3 Selectivity and specificity data of both compounds [18]
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is an urgent need for a ligand with high affinity and selectivity
for this receptor. The findings of this and previous studies
indicate the potential of FE@SUPPY in this role, and provide
further evidence to support the use of [18F]FE@SUPPY as a
specific PET tracer for the noninvasive visualization of A3R-
related pathologies. However, we are of the view that in vivo
studies of [18F]FE@SUPPY in animal models have to be per-
formed before its use in humans (e.g. for tumour imaging) can
seriously be recommended.
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